- Home
- GLRE vs ZNTL Comparison
GLRE vs ZNTL Comparison
Compare GLRE & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | ZNTL |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 468.9M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLRE | ZNTL |
|---|---|---|
| Price | $18.55 | $4.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 232.1K | ★ 3.9M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | 18.03 |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.48 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $1.13 |
| 52 Week High | $19.25 | $6.95 |
Technical Indicators
Market Signals| Indicator | GLRE | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 69.85 | 59.28 |
| Support Level | $12.49 | $1.53 |
| Resistance Level | N/A | $6.95 |
| Average True Range (ATR) | 0.52 | 0.71 |
| MACD | -0.04 | 0.20 |
| Stochastic Oscillator | 74.39 | 51.33 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.